Centauri Therapeutics Limited

United Kingdom - London

• 25/02/2026
• Series A
• $8,107,170

Centauri Therapeutics Limited is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases.

The Alphamer technology is based on "programmable immunity"​ in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.

Related People

Jennifer SchneiderFounder

United Kingdom - London, England

At Centauri Therapeutics, we are using immunotherapy to treat infectious diseases, including in those patients who are underserved by current therapeutic modalities. Our Alphamer platform is transformative and allows a new, precision approach, to treat patients with life-threatening infectious disease. Alphamers leverage a patient's immune system, harnessing pre-existing anti-glycan antibodies to induce a pathogen-directed immune response. Currently we are focusing our technology on bacterial infections including multi-drug resistant strains. This technology has enormous potential in the fight against antimicrobial resistance, including for the most vulnerable patients.

LinkedIn https://www.linkedin.com/in/jennifer-schneider-9535b430/